Skip to main content
SpringerLink
Log in

Factors Influencing Family Physician Adherence to Hypertension Treatment Guideline Recommendations on the Initiation of Pharmacotherapy

Questionnaire Survey

  • Original Research Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Background

Family physicians do not prescribe antihypertensive medication according to current guidelines. This study investigates possible reasons for this. The objectives were to measure the knowledge, attitude and stated practice of family physicians to the initiation of pharmacotherapy for uncomplicated hypertension and to explore the reasons why clinical practice differs from guideline recommendations.

Study design

A cross-sectional postal survey conducted between June and October 1999. Simple frequency analysis and a χ2 test comparing family physician characteristics and responses.

Methods

A three-phase postal survey was undertaken of a random sample of family physicians. Telephone and facsimile contact was made to non-responders. The survey instrument included respondent characteristics, preference for initiation of antihypertensive drug therapy and their opinion of efficacy, adverse effects and long-term safety, as well as knowledge of guidelines.

Participants

Family physicians in the state of Victoria, Australia.

Main outcome measures and results

Ranked preference of drugs for uncomplicated hypertension. Opinion of drug efficacy, adverse effects, safety and cost. Knowledge of guidelines for first-line antihypertensive drugs. Newer agents are preferred to older agents in the initiation of antihypertensive drug therapy contrary to current guideline recommendations. Newer agents were thought to be more efficacious, have better short- and long-term adverse effect profiles and be more expensive than older agents. Younger doctors most often held these attitudes. Guidelines influenced decision making but were not the most important factor.

Conclusions

There is a demonstrable need for governments to invest in the promotion of accurate information on drugs through continuing education of prescribers and facilitating the production of standardized paper and web-based clinical guidelines. A program of targeted investment in clinical trials that examine the justification for more expensive classes of agents should also be considered in appropriate circumstances.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157(24): 2413–46

    Google Scholar 

  2. Ramsay L, Williams B, Johnston GD, et al. Guidelines for the management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569–92

    Article  PubMed  CAS  Google Scholar 

  3. Guidelines Subcommittee. 1999 World Health Organization: International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–83

    Google Scholar 

  4. Consensus Panel. The management of hypertension: a consensus statement. Med J Aust 1994; 160: S1–S16

    Google Scholar 

  5. National Blood Pressure Advisory Committee. 1999 guide to management of hypertension for doctors. Canberra: National Heart Foundation of Australia, 1999

    Google Scholar 

  6. Hansson L, Lindholm, LH, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354(9192): 1751–6

    Article  PubMed  CAS  Google Scholar 

  7. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-convertingenzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6

    Article  PubMed  CAS  Google Scholar 

  8. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356(29): 366–72

    Article  PubMed  CAS  Google Scholar 

  9. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356(29): 359–65

    Article  PubMed  CAS  Google Scholar 

  10. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT). JAMA 2002; 288: 2981-97

  11. Dahlöf B, Devereux R, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359: 995–1003

    Article  PubMed  Google Scholar 

  12. Wing LMH, Reid CM, Ryan P. A comparison of outcomes with angiotensinconverting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7): 583–92

    Article  PubMed  CAS  Google Scholar 

  13. Analysis Section, Pharmaceutical Benefits Branch. Expenditure and prescriptions twelve months to 31 December 1998. Canberra: Commonwealth Department of Health and Aged Care, 1999

    Google Scholar 

  14. Whitfield M, Hughes A. Hypertension management in family practice. J R Soc Med 1997; 90: 12–5

    PubMed  CAS  Google Scholar 

  15. Troein M, Gardell B, Seiander S, et al. Guidelines and reported practice for the treatment of hypertension and hypercholesterolaemia. J Intern Med 1997; 242: 173–8

    Article  PubMed  CAS  Google Scholar 

  16. Avanzini F, Tognoni G, Alli C, et al. How informed family physicians manage mild hypertension: a survey of readers of drug bulletins in 7 countries. Eur J Clin Pharmacol 1996; 6: 445–50

    Article  Google Scholar 

  17. Arroll B, Jenkins S, North D, et al. Management of hypertension and the core services guidelines: results from interviews with 100 Auckland family physicians. N Z Med J 1995 Feb 22; 108(994): 55–7

    PubMed  CAS  Google Scholar 

  18. Mazzeo F, Motola G, Rossi S, et al. Management of hypertension by family physicians: an Italian observational study. Adv Ther 2001 May-Jun; 18(3): 122–30

    Article  PubMed  CAS  Google Scholar 

  19. General Practice Workforce 1998–1999. General practice workforce series B. Number of medical practitioners billing Medicare, by state/territory and type of practitioner. Commonwealth Department of health and aged care. Available from URL: http://www.health.gov.auhsdd/gp/stats/workforce/b1999w.htm [Accessed 2003 Nov 19]

  20. General Practice Workforce 1998–1999. General practice workforce series L. Recognised general practitioners billing Medicare, by age, practitioner type and gender, 1998–1999. Available from URL: http://www.health.gov.au/hsdd/gp/ stats/workforce/1999w.htm [Accessed 2003 Nov 19 ]

  21. Nelson MR, Reid CM, Peeters, et al. PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia 1994–1998. Med J Aust 2001; 174: 565–8

    PubMed  CAS  Google Scholar 

  22. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328(13): 914–21

    Article  Google Scholar 

  23. Neaton JD, Grimm Jr RH, Prineas RJ, et al. Treatment of mild hypertension study: final results. JAMA 1993; 270: 713–24

    Article  PubMed  CAS  Google Scholar 

  24. Grimm Jr RH, Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997; 157: 638–48

    Article  PubMed  Google Scholar 

  25. NHMRC A guide to the development, implementation and evaluation of clinical practice guidelines. Ausinfo, Canberra 1999.

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Prahran, 3181, Australia

    Mark R. Nelson

  2. CVD Prevention Unit, Baker Medical Research Institute, Alfred Hospital, Prahran, Australia

    Chris M. Reid, Henry Krum & John J. McNeil

Authors
  1. Mark R. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chris M. Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henry Krum
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John J. McNeil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark R. Nelson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nelson, M.R., Reid, C.M., Krum, H. et al. Factors Influencing Family Physician Adherence to Hypertension Treatment Guideline Recommendations on the Initiation of Pharmacotherapy. Am J Cardiovasc Drugs 3, 437–441 (2003). https://doi.org/10.2165/00129784-200303060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200303060-00006

Keywords

Search

Navigation